AR
AREVF.US AREV NanoTec Brands Inc
- Market cap
- USD 15.9K
- P/E
- -
- P/B
- 1.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is AREVF.US undervalued?
Graham numberThe Graham number of AREV NanoTec Brands Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AREV NanoTec Brands Inc fundamental analysis
No fundamental analysis for AREV NanoTec Brands Inc yet.
AREV NanoTec Brands Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AREV NanoTec Brands Inc
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company's pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinic…
Full company profileAREV NanoTec Brands Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
AREV NanoTec Brands Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 195K | 191K | 255K | 49.1K | 0.00 |
| Gross Profit | - | -44.8K | -356.00 | -7.20K | -51.6K | -52.5K | 129K | 191K | 185K | 29.1K | -55.4K |
| Operating Income | -33.8K | -29.9K | -82.0K | -226K | -849K | -1.69M | -3.03M | -452K | -1.50M | -1.39M | -397K |
| EBITDA | -33.6K | -29.6K | -81.6K | -219K | -797K | -1.64M | -3.05M | -452K | -798K | -1.31M | -366K |
| Net Income | -34.0K | -75.2K | -84.2K | -252K | -1.02M | -8.43M | -3.19M | -1.05M | -990K | -1.44M | -425K |
| EPS | -6.23 | -13 | -16 | -24 | -0.42 | -1.47 | -0.36 | -0.07 | -0.04 | -0.05 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 52.8K | 3.50K | 17.3K | 794K | 1.66M | 530K | 879K | 1.28M | 623K | 253K | 213K |
| Total Liabilities | 57.8K | 83.7K | 182K | 610K | 700K | 757K | 1.41M | 1.92M | 716K | 1.21M | 1.38M |
| Shareholders' Equity | -4.96K | -80.2K | -164K | 184K | 959K | -226K | -526K | -641K | -93.5K | -953K | -1.16M |
| Cash & Short-term Investments | 5.85K | 1.70K | 1.72K | 194K | 1.06M | 8.37K | 29.7K | 298K | 158K | 94.00 | 1.82K |
| Total Debt | - | - | 51.8K | 363K | 285K | 428K | 573K | 736K | 75.7K | 28.8K | 145K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -28.6K | -4.15K | -48.6K | -111K | -448K | -1.25M | -114K | -23.5K | -1.47M | -284K | -195K |
| Capital Expenditure | 0.00 | 0.00 | 3.20K | 4.55K | 113K | 50.0K | 215K | 456K | 12.0K | 81.8K | 10.59 |
| Free Cash Flow | -28.6K | -4.15K | -51.8K | -116K | -561K | -1.30M | -329K | -480K | -1.48M | -366K | -195K |
| Ratios | |||||||||||
| ROE | - | - | - | -137.0% | -106.3% | - | - | - | - | - | - |
| ROA | -64.4% | -2,147.4% | -485.4% | -31.7% | -61.5% | -1,589.3% | -363.1% | -82.1% | -159.1% | -571.6% | -199.5% |
| Net Profit Margin | - | - | - | - | - | - | -1,640.0% | -550.4% | -388.4% | -2,940.4% | - |
| Debt to Equity | - | - | - | 1.98x | 0.30x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AREV NanoTec Brands Inc dividends
AREV NanoTec Brands Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Mar 19, 2020.
Who owns AREV NanoTec Brands Inc
- Insiders 47.41%
- Institutions 0.00%
- Public & others 52.60%
- Shares outstanding 31.8M
- Free float 16.8M
AREV NanoTec Brands Inc company profile
- Company name
- AREV NanoTec Brands Inc
- Ticker
- AREVF.US
- ISIN
- CA04019J1093
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 18 - 91 Golden Drive, Coquitlam, BC, Canada, V3K 6R2
- Phone
- 604 803 8439
- Website
- arevlifesciences.com
About AREV NanoTec Brands Inc
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company's pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinical need for rational enhanced caloric intake and micronutrient supplementation. It also develops edible oils, moringa, hops, cannabis sativa, pharma, sea cucumber, ginseng, and functional fungi ingredients; and anti-virals and phytomedicinalization. In addition, the company flash-freezes active ingredients, oils, and oleoresins for use as ingredients in food, nutraceuticals, and other consumer products. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. is based in Coquitlam, Canada.
AREV NanoTec Brands Inc management
3- Mr. Michael C. WithrowChairman & CEO · born 1963
- Ms. Denby GreensladeInterim CFO, Corporate Secretary & Director
- Mr. Donald ShaxonVice President of Marketing